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Abstract
Purpose The molecular landscape of breast cancer (BC),
especially of the Luminal A subtype, remains to be fully
delineated. Transcriptomic data show that Luminal A
tumours are enriched for aberrant expression of genes in
the cell division control 42 homolog (CDC42) pathway.
This study aims to investigate the protein expression of
CDC42 in BC and assess its clinicopathological
significance.
Methods Expression of CDC42 protein was examined by
immunohistochemistry on tissue microarrays in a well-
characterised cohort of 895 early-stage (I–IIIa) primary
invasive BCs.
Results CDC42 expression was observed in both the
cytoplasm and the nucleus of BC cells. High nuclear
CDC42 expression demonstrated a significant correlation
with ER-positive, low-grade tumours and was more com-
mon in the lobular histological subtype (all p\ 0.001). In
contrast, cytoplasmic CDC42 showed increased expression
in the ductal subtype (p\ 0.001) and correlated with
negative prognostic features such as larger size, higher
grade (p\ 0.05) and higher Ki67 labelling index
(p = 0.001). Nuclear CDC42 expression was associated
with a longer BC-specific survival in all cases (p = 0.025)
and in luminal ER-positive tumours (p = 0.011). In mul-
tivariate analyses including size, grade, lymph node stage
and intrinsic subtype, CDC42 was an independent prog-
nostic factor (p = 0.032).
Conclusion The results indicate that CDC42 is an impor-
tant molecule in luminal BC, with prognostic significance.
Keywords CDC42  Immunohistochemistry  Luminal
breast cancer  Prognosis
Introduction
Breast cancer (BC) is a heterogeneous disease with mul-
tiple subtypes related to the oestrogen receptor (ER) status,
the presence of ERBB2 amplification and also the genetic
and transcriptomic landscape. While large genomic studies
have identified subgroups with different clinical outcomes
[1–3], the aberrant pathways driven by the various genetic
aberrations identified in these subgroups remain to be
elucidated. In particular, studies are required to resolve the
landscape of the Luminal A intrinsic subtype, the most
common molecular subtype of BC. This group of ER-
positive tumours are usually low grade and have a good
prognosis with a good response to hormone therapy.
However, a small subset of Luminal A tumours will pro-
gress and clinically recur.
Based on genomic and transcriptomic analysis by the
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Consortium (METABRIC) group, Luminal A tumours are
enriched for aberrant expression of genes in the cell divi-
sion control 42 homolog (CDC42) pathway [2] and linked
by low levels of copy number aberration. The protein
kinase signalling pathway protein CDC42 is a plasma
membrane-associated small GTPase which phases between
an active GTP-bound and an inactive GDP-bound state [4].
When CDC42 is in an active state, it binds to a variety of
effector proteins to control various cellular procedures such
as regulation of the actin cytoskeleton, cell migration and
progression through G1 phase of the cell cycle to enter S
phase for DNA synthesis.
CDC42 is expressed at low levels in normal breast tissue
and elevated in breast carcinomas [5], with an essential role
in normal mammary development [6]. Despite the impor-
tance of the Rho-GTPase pathway in BC, CDC42 protein
expression has not been evaluated in a large cohort of BCs
with clinical outcome data. This study was thus conducted
to investigate the role of CDC42 protein in invasive BCs
including correlations with other BC-related biomarkers,
clinicopathological variables and disease outcome.
Materials and methods
Study cohort
This study was conducted on the well-characterised Not-
tingham Tenovus Primary Breast Carcinoma series
(n = 1048), which includes patients at Nottingham City
Hospital between 1990 and 1998. The study was approved
by the Nottingham Research Ethics Committee 2. Patients
were under the age of 70 years and managed in a uniform
manner [7]. Clinicopathological parameters recorded
include histological tumour type, tumour size, grade and
axillary lymph node stage. The series is also annotated with
an immunohistochemical repository of a wide range of
biomarkers including hormone receptors [oestrogen
receptor (ER), progesterone receptor (PgR)], epidermal
growth factor receptor family (EGFR and HER2), cytok-
eratins (basal cytokeratin: CK5/6), the proliferation marker
Ki67 and E-cadherin [7]. Survival data were analysed
prospectively with disease-specific survival (DSS) defined
as the interval in months from primary surgery to patient
death caused by BC.
Western blotting
For validation of CDC42 antibody specificity, Western
blotting was performed on whole cell lysates of MCF-7,
SKBr3 and MDA-MB231 human breast cancer cell lines
(obtained from the American Type Culture Collection;
Rockville, MD, USA) using CDC42 antibody (clone PA1-
092) at 1:1000 dilution and fluorescent secondary anti-
bodies at 1:15,000 were used (IR Dye 800CW donkey anti-
rabbit and 680RD donkey anti-mouse, LI-COR Bio-
sciences, UK). 5% milk (Marvel original dried skimmed
milk, Premier Food Groups Ltd, St Albans, UK) was used
for blocking. Mouse b-Actin (A5441, Sigma-Aldrich;
Clone AC-15; Sigma, UK) at 1:5000 was used as a house-
keeping protein. A protein ladder (PageRuler Plus Pre-
stained Protein Ladder, ThermoScientific, Waltham, MA,
USA) was included. The fluorescence was then detected
using the LI-COR Odyssey Fc machine to visualise the
bands, with wavelengths 600, 700 and 800.
Immunohistochemistry
Expression of the CDC42 protein in BC was assessed by
immunohistochemistry (IHC), using the Novocastra
Novolink polymer detection system (Leica, Newcastle,
UK). In brief, BC tissue microarray (TMA) sections were
deparaffinised with xylene and rehydrated through 100%
ethanol. Heat-induced retrieval of antigen epitopes was
performed in citrate solution (pH 6.0). TMAs were stained
with CDC42 antibody (clone PA1-092, 1:30) for 30 min.
3,30-Diaminobenzidine tetrahydrochloride (Novolink DAB
substrate buffer plus) was used as a chromogenic sub-
stance. TMA sections were counterstained with haema-
toxylin for 6 min. Human tonsil sections were used as a
positive control while a negative control was achieved by
omitting the application of the primary antibody.
Immunohistochemical scoring
Stained TMAs were scored using the semi-quantitative
H-score (Histochemical score) visual approach taking into
consideration the intensity of staining and the percentage of
stained cells within each tissue core [8]. Both nuclear and
cytoplasmic staining were scored separately: staining
intensity was scored as 0, 1, 2 or 3 for negative, weak,
moderate and strong, respectively. Final scores were
obtained by multiplying each staining intensity by its
proportion, summed up as an H-score ranging from 0 to
300. All cases were scored blinded to clinicopathological
and outcome data. TMAs were double scored for inter-
observer variation.
Analysis of external datasets
Publically available normalised gene expression (RNAseq)
and protein mass spectrometry data, as well as clinico-
pathologic information, were downloaded from the Cancer
GenomeAtlas (TCGA, [1]) data portal. Gene expression and
clinicopathologic information were also obtained from
METABRIC collaborators [2]. All analyses were performed
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in the program R. The results published here are, in part,
based on data generated by TCGA project established by the
NCI and NHGRI. Information about TCGA and the inves-
tigators and institutions who constitute the TCGA research
network can be found at http://cancergenome.nih.gov.
Statistical analysis
Three groups were used for correlation analyses—negative
(H-score = 0), low (H-score 10–150) and high (H-
score[ 150). Statistical analyses were performed in
the program R. Correlations were assessed using the Chi-
square test (v2 test). Cox regression analysis was performed
for survival analysis (coxph), reporting the log-rank test.
StepAIC was used for Akaike information criterion mod-
elling. A p value of\0.05 (two-sided) was considered to be
statistically significant.
Results
Analysis of METABRIC and TCGA data
Genomic profiling of BC by the METABRIC consortium
encompassing gene expression and copy number data
identified ten molecular subtypes called ‘‘integrative clus-
ters’’ (ICs) [2]. The Luminal A type tumours were seen to
group in clusters IC3, IC4, IC7 and IC8. We noted that
CDC42 signalling was a highly ranked pathway in the IC4
group in the METABRIC study, and was also positively
associated with IC3. In contrast, this pathway scored a zero
in the other Luminal A-dominated clusters IC7 and IC8.
We hypothesised that CDC42 signalling could be useful in
delineating a subgroup of Luminal A tumours with dif-
ferent phenotypic characteristics. We focused on the cen-
tral signalling protein in this pathway, CDC42. Further
exploration of the genomics data in the METABRIC cohort
found that while CDC42 itself was differentially expressed
between integrative clusters, the highest mRNA expression
was not found in either IC3 or IC4 (Supplementary
Fig. 1A). However, analysis of The Cancer Genome Atlas
(TCGA) mRNA and protein mass spectrometry data
showed that CDC42 mRNA and protein were poorly cor-
related (Spearman r = 0.16, p = 0.09, Supplementary
Fig. 1B). Thus, CDC42 mRNA alone may not be a good
proxy for CDC42 protein expression or pathway activation.
Expression of CDC42 by immunohistochemistry
CDC42 showed both nuclear and cytoplasmic staining in
the invasive tumour cells (Fig. 1a). Nuclear and cytoplas-
mic expression were positively correlated (Spearman
r = 0.38, p\ 0.001). However, for those cases that were
part of the METABRIC study (n = 143), there was no
correlation between IHC H-score and mRNA expression by
microarray, consistent with TCGA mRNA/mass spec-
trometry data (nuclear staining Spearman r = -0.097,
p = 0.25; cytoplasmic staining r = -0.12, p = 0.14,
Supplementary Fig. 1C). The specificity of the antibody
was validated by Western blotting analysis, which showed
a single specific band at the predicted size (23 kDa)
(Fig. 1b).
The distribution of H-scores from the 895 successfully
scored cases suggested tri-modality for both nuclear and
cytoplasmic staining, with peaks at 0, 100 and 220 for
nuclear, and 0, 100 and 200 for cytoplasmic (Fig. 1c).
Three groups were therefore evaluated for correlation with
phenotypic tumour features—negative (H-score = 0), low
(H-score 10–150) and high (H-score[ 150).
Correlations with clinicopathological parameters
Nuclear CDC42 expression showed significant negative
associations with tumour grade (p\ 0.001), tumour size
(p\ 0.001) and HER2 status (p = 0.018) but a positive
correlation with ER status (p\ 0.001) (Tables 1, 2). His-
tological subtype was also significantly associated with
CDC42 nuclear staining (p\ 0.001, Fig. 2): lobular types
had a higher proportion of cases with high nuclear
expression of CDC42 (65.5%), compared to ductal types
(38.6% high expression). Thus, high nuclear expression of
CDC42 was strongly associated with tumours carrying
good prognostic features such as low grade, non-ductal
histology, ER positivity, HER2 negativity and smaller size.
In contrast, high cytoplasmic CDC42 expression is more
common in cases with a ductal histology (53.8%) than
lobular (21.8%). CDC42 cytoplasmic staining also showed
correlations with tumour size (p = 0.04) and grade
(p = 0.014).
We tested for an association of CDC42 with intrinsic
subtype using the Gallen IHC system [9], whereby Luminal
A tumours are defined as ER?, Ki67-low, Luminal B are
ER? and either Ki67-high or HER2?, HER2 tumours are
ER-, HER2?, and Negative tumours are ER-, HER2-.
High nuclear CDC42 staining was strongly correlated with
the Luminal-type tumours (p\ 0.001, Table 2). Cases with
low CDC42 were significantly more likely to be triple
negative for ER, PR and HER2 (28.8% vs 16.6%,
p =\0.001).
For the subset of cases that were part of the METABRIC
cohort (n = 144), we tested whether CDC42 IHC H-scores
were associated with integrated cluster membership. A
statistically significant association of nuclear CDC42
staining with IC subgroup was found (p = 0.04, one-way
ANOVA, Supplementary Fig. 2). In particular, high
CDC42 nuclear staining was most prevalent in the luminal
Breast Cancer Res Treat (2017) 164:317–325 319
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IC groups: IC3 (46% high CDC42), IC4 (50%), IC7 (82%)
and IC8 (71%) compared to all others (20%); however,
Tukey post-tests were not significant, most likely due to the
small number of cases in each group. Cytoplasmic CDC42
staining was not associated with integrative cluster mem-
bership (p = 0.14).
We compared CDC42 nuclear staining with the
expression of other important breast cancer proteins for
which IHC data were also available (Table 2). Significant
negative associations were observed with Ki67 (p = 0.035)
and EGFR (p = 0.023), and a positive correlation was
observed with basal cytokeratin CK5/6 (p = 0.003), but
A
B
C
D
E
F
Fig. 1 Expression of CDC42 in breast cancer. a Western Blotting
analysis using anti-CDC42 Polyclonal Antibody (PA1-092) showing
band at the expected size (23 kDa). b CDC42 expression in terminal
duct lobular units using IHC. c CDC42 expression in TMA cores
using IHC. Intensity levels of staining are shown: 1 negative, 2 weak,
3 moderate and 4 strong expression (920 magnification).
d Histograms of H-scores for nuclear and cytoplasmic staining.
e Distribution of cases across different histological subtypes, showing
the increased proportion of lobular cases with high CDC42 nuclear
staining but low or negative cytoplasmic staining. f Example of
lobular carcinoma showing strong nuclear staining
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not E-cadherin. Cytoplasmic CDC42 showed positive
correlations with the expression of Ki67 (p = 0.001) and
E-cadherin (p\ 0.001) but not EGFR, or CK5/6.
In TCGA mass spectrometry data, the association of
CDC42 protein expression and EGFR protein levels was
validated (Spearman r = 0.25, p = 0.01); however, other
associations were of either borderline significance (E-cad-
herin r = 0.19, p = 0.059,Ki67 r = 0.16, p = 0.099) or not
significant (CK5/6 r = 0.003, p = 0.97). This is perhaps not
surprising given the different directions of associations seen
with nuclear versus cytoplasmic staining by IHC.
Correlation with patient outcome
In a univariate analysis using the IHC H-scores, high
CDC42 nuclear staining was significantly associated with
improved disease-specific survival (DSS) (Fig. 2, likeli-
hood ratio test, p = 0.025). Similarly, there was a bor-
derline significant result for nuclear CDC42 staining to
affect disease-free survival (DFS) (p = 0.0885). Because
CDC42 nuclear staining was strongly associated with ER-
positive status, we also performed a subgroup analysis,
stratified by ER status. CDC42 nuclear staining was still
associated with DSS in ER-positive cases (p = 0.011,
Fig. 2), but not ER-negative cases (p = 0.65). Similar to
the full cohort, CDC42 was associated with DFS with only
borderline significance in ER-positive cases (p = 0.08). No
association with patient DSS or DFS was observed for
cytoplasmic CDC42 staining in either the full cohort or by
ER status.
Multivariate survival analysis to evaluate the impact of
other factors on survival including lymph node stage,
grade, tumour size, ER status and HER2 status found that
in both the full and ER-positive cohorts, CDC42 nuclear
staining was not an independent prognostic factor
(p = 0.17, p = 0.086, respectively, Table 3). However, we
also performed Akaike information criterion modelling,
including lymph node stage, grade, tumour size, histolog-
ical subtype and Gallen subtype. Nuclear CDC42 staining
was included in the final model for both DSS and DFS, and
was individually significant in each model (DSS,
p = 0.032, DFS, p = 0.031, Table 3). Cytoplasmic
CDC42 staining was not included in any survival model.
Discussion
In the present study, we investigated the expression of
CDC42 in a heterogeneous group of patients with invasive
BC. CDC42 overexpression has been reported in several
Table 1 Correlation of CDC42 protein expression with clinicopathological parameters
Nuclear Cytoplasmic
Feature Negative Low High p value (v2) Negative Low High p value (v2)
Age (years)
C50 110 (19.2%) 231 (40.4%) 231 (40.4%) 0.70 (0.702) 48 (8.4%) 241 (42.1%) 283 (49.5%) 0.33 (2.23)
\50 56 (17.8%) 123 (39.0%) 136 (43.2%) 18 (5.7%) 132 (42.0%) 164 (52.2%)
Size (mm)
C20 105 (22.5%) 198 (42.5%) 163 (35.0%) <0.001 (18.1) 40 (8.6%) 208 (44.7%) 217 (46.7%) 0.039 (6.47)
\20 63 (14.8%) 157 (36.9%) 205 (48.2%) 26 (6.1%) 166 (39.1%) 233 (54.8%)
Grade
1 24 (19.4%) 45 (36.3%) 55 (44.4%) <0.001 (28.8) 8 (6.5%) 54 (43.5%) 62 (50.0%) 0.014 (12.5)
2 36 (12.0%) 109 (36.3%) 155 (51.7%) 33 (11.0%) 134 (44.7%) 133 (44.3%)
3 107 (23.1%) 200 (43.1%) 157 (33.8%) 25 (5.4%) 186 (40.2%) 252 (54.4%)
Lymph node stage
1 115 (21.1%) 214 (39.3%) 216 (39.6%) 0.24 (5.48) 44 (8.1%) 235 (43.2%) 265 (48.7%) 0.29 (5.004)
2 43 (15.8%) 111 (40.8%) 118 (43.4%) 14 (5.1%) 112 (41.2%) 146 (53.7%)
3 9 (12.7%) 29 (40.8%) 33 (46.5%) 8 (11.3%) 27 (38.0%) 36 (50.7%)
Histological type
Ductal 150 (20.2%) 306 (41.2%) 287 (38.6%) <0.001 (36.4) 36 (4.9%) 307 (41.4%) 399 (53.8%) p < 0.001 (76.1)
Lobular 4 (4.6%) 26 (29.9%) 57 (65.5%) 23 (26.4%) 45 (51.7%) 19 (21.8%)
Medullary 7 (31.8%) 10 (45.5%) 5 (22.7%) 4 (18.2%) 7 (31.8%) 11 (50.0%)
Mucinous 0 (0.0%) 2 (28.6%) 5 (71.4%) 0 (0.0%) 1 (14.3%) 6 (85.7%)
Tubular 2 (11.8%) 6 (35.3%) 9 (52.9%) 1 (5.9%) 9 (52.9%) 7 (41.2%)
Other 5 (33.3%) 5 (33.3%) 5 (33.3%) 2 (13.3%) 5 (33.3%) 8 (53.3%)
Significant p values are represented in bold
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Table 2 Correlation of CDC42 protein expression with other biomarkers
Nuclear Cytoplasmic
Feature Negative Low High p value (v2) Negative Low High p value (v2)
Oestrogen receptor
Negative 64 (27.7%) 94 (40.7%) 73 (31.6%) <0.001 (19.6) 14 (6.1%) 96 (41.6%) 121 (52.4%) 0.59 (1.05)
Positive 104 (15.9%) 259 (39.5%) 292 (44.6%) 52 (8.0%) 276 (42.2%) 326 (49.8%)
Progesterone receptor
Negative 87 (24.2%) 149 (41.4%) 124 (34.4%) <0.001 (15.8) 24 (6.7%) 166 (46.1%) 170 (47.2%) 0.14 (4.00)
Positive 74 (14.9%) 196 (39.6%) 225 (45.5%) 38 (7.7%) 194 (39.3%) 262 (53.0%)
HER2 status
Negative 131 (17.8%) 289 (39.3%) 316 (42.9%) 0.018 (8.08) 58 (7.9%) 314 (42.7%) 363 (49.4%) 0.28 (2.57)
Positive 31 (25.2%) 55 (44.7%) 37 (30.1%) 7 (5.7%) 46 (37.4%) 70 (56.9%)
Triple negative
Non-triple 118 (16.6%) 284 (39.9%) 310 (43.5%) <0.001 (16.2) 53 (7.5%) 300 (42.2%) 358 (50.4%) 0.99 (0.029)
Triple 44 (28.8%) 64 (41.8%) 45 (29.4%) 12 (7.8%) 64 (41.8%) 77 (50.3%)
Intrinsic subtype
ER-, HER2? 14 (25.0%) 24 (42.9%) 18 (32.1%) <0.001 (24.3) 1 (1.8%) 23 (41.1%) 32 (57.1%) 0.083 (11.2)
Luminal A 25 (12.5%) 76 (38.0%) 99 (49.5%) 20 (10.0%) 95 (47.5%) 85 (42.5%)
Luminal B 58 (16.5%) 148 (42.2%) 145 (41.3%) 22 (6.3%) 137 (39.1%) 191 (54.6%)
ER-, HER2- 46 (28.6%) 66 (41.0%) 49 (30.4%) 12 (7.5%) 68 (42.2%) 81 (50.3%)
Ki67
\10% 32 (13.9%) 88 (38.3%) 110 (47.8%) 0.035 (6.7) 24 (10.4%) 109 (47.4%) 97 (42.2%) 0.001 (13.7)
C10% 101 (20.1%) 206 (41.0%) 195 (38.8%) 25 (5.0%) 202 (40.3%) 274 (54.7%)
E-cadherin
Negative/low 59 (18.8%) 134 (42.8%) 120 (38.3%) 0.50 (1.39) 33 (10.6%) 148 (47.4%) 131 (42.0%) <0.001 (19.4)
Positive 96 (18.4%) 205 (39.3%) 221 (42.3%) 26 (5.0%) 204 (39.1%) 292 (55.9%)
EGFR
Negative 120 (17.4%) 268 (38.8%) 303 (43.8%) 0.023 (7.52) 57 (8.3%) 285 (41.3%) 348 (50.4%) 0.16 (3.71)
Positive 39 (22.3%) 79 (45.1%) 57 (32.6%) 7 (4.0%) 75 (42.9%) 93 (53.1%)
CK5/6
Negative 237 (42.2%) 224 (39.9%) 101 (18.0%) 0.003 (11.75) 286 (50.9%) 238 (42.3%) 38 (6.8%) 0.443 (1.63)
Positive 29 (25.9%) 52 (46.4%) 31 (27.7%) 59 (52.7%) 49 (43.8%) 4 (3.6%)
Significant p values are represented in bold
Fig. 2 Kaplan–Meier plots for CDC42 nuclear expression: in all cases, ER-positive cases and ER-positive/HER2-negative cases
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other malignancies [10–14], including invasive breast
ductal carcinomas [5, 15]. CDC42 was expressed in a
higher frequency in the cytoplasm (92.4%) than in the
nucleus (80.7%) in our BC cohort, similar to the observa-
tions of Halon et al., who found a predominant cytoplasmic
localisation of CDC42 [15]. We identified different phe-
notypic correlations of nuclear versus cytoplasmic
expression of CDC42, with high nuclear expression cor-
relating with better prognostic features. This result is
consistent with the study performed by Halon et al., where
nuclear expression was inversely correlated with lymph
node metastasis. However, this earlier study was too small
(n = 85) to demonstrate a significant survival difference as
shown here for nuclear CDC42 expression.
In the cytoplasm, CDC42 acts as a regulator of signal
transduction pathways involved in the remodelling of the
actin cytoskeleton and regulation of cell polarity [16] and
also plays an important role in controlling cell proliferation
and stimulating cell cycle progression through G1 phase to
S phase via c-Jun [17]. In the present study, we found that
higher CDC42 cytoplasmic expression was associated with
increased expression of Ki67, whereas the nuclear com-
ponent showed no correlation to proliferation markers. This
result is similar to that seen by Ma et al. [13] in their large
(n = 339) analysis of breast tumours, although subcellular
localisation was not recorded, nor was survival information
available. They also observed a positive correlation with
TNM stage and lymph node metastasis, which we did not
see.
Interestingly, we found an association of CDC42 nuclear
expression with special histological tumour types such as
lobular and tubular tumours. These tumour types have
distinct morphologies e.g. a single cell pattern in the lobular
type and tubule formation in the tubular type. As CDC42 is
important in cytoskeleton remodelling, it could be involved
in contributing to the morphology of these tumours. Indeed,
CDC42 overexpression in mouse epithelial mammary cells
in vivo leads to hyperbranching of ducts and abnormal
terminal end bud morphology [18]. Lobular carcinoma cells
are discohesive by nature and loss of E-cadherin is a hall-
mark of lobular carcinoma. CDC42 GTPase-activating
protein (CdGAP) uses its proline-rich domain to form a
complex with the epithelial–mesenchymal transition regu-
lator Zeb2 to repress E-cadherin expression [19]. This may
be one of the underlying molecular pathways leading to the
morphological lobular appearance.
The significance of the presence of CDC42 in the
nucleus is unclear, as the literature does not suggest an
Table 3 Multivariate survival
analysis
Hazard ratio 95% confidence interval p value
All (DSS)
CDC42 nuclear H-score 0.999 0.998–1.00 0.176
Size\ 20 mm 0.705 0.57–0.93 0.005
Grade 1.582 1.25–1.88 9.1 3 1026
Lymph node stage 1.762 1.44–2.04 7.2 3 10211
ER? status 1.091 0.83–1.43 0.530
HER2? status 1.555 1.12–2.00 0.003
ER positive (DSS)
CDC42 nuclear H-score 0.999 0.997–1.00 0.086
Size\ 20 mm 0.713 0.535–0.95 0.021
Grade 1.626 1.315–2.01 7.2 3 1026
Lymph node stage 1.749 1.423–2.15 1.1 3 1027
HER2? status 1.529 1.051–2.23 0.027
Akaike (DSS)
CDC42 nuclear H-score 0.999 0.997–1.00 0.032
Size\ 20 mm 0.730 0.562–0.95 0.018
Grade 1.379 1.081–1.76 0.010
Luminal A 3.902 0.885–17.20 0.072
Luminal B 3.643 0.990–13.41 0.052
ER/HER2 Negative 3.382 0.840–13.62 0.086
Lymph node stage 4.440 2.373–8.31 3.1 3 1026
Luminal A: stage 0.269 0.121–0.60 0.001
Luminal B: stage 0.409 0.211–0.79 0.008
ER/HER2 Negative: stage 0.365 0.176–0.76 0.007
Significant p values are represented in bold
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active role for the protein in this subcellular compartment.
However, the related protein Rac1 has been shown to be
sequestered in the nucleus for ubiquitin-mediated prote-
olytic degradation [20], and possibly for an active role
related to proliferation [21]. CDC42 is also susceptible to
such degradation [22] and contains a conserved C-terminal
nuclear localisation signal that could mediate transfer to the
nucleus [23]. Therefore, one possibility is that CDC42 is
also degraded in the nucleus, and its presence there in
breast cancer could represent some deregulation of normal
protein turnover. Alternatively, as for Rac1, CDC42 may
play a as yet to be determined role in the nucleus that is
active in breast cancer cells.
In conclusion, CDC42 seems to be a key determinant of
low-grade ER-positive breast cancers with prognostic sig-
nificance. Subcellular localisation may be important in
determining breast cancer morphology and further func-
tional studies in morphological subtypes are warranted.
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